Ovarian cancer is the second leading cause of gynecologic cancer deaths globally, with complex outcomes due to late diagnosis and diverse subtypes. Treatment primarily involves debulking surgery and platinum-based chemotherapy, with antiangiogenic agents added for suboptimal debulked and stage IV disease. Recent advancements include the use of PARP inhibitors in maintenance therapy for recurrent and first-line settings, especially in BRCA1/BRCA2 mutation carriers. Deep molecular and cellular profiling are enhancing current investigations, and individualized precision medicine is crucial for improving survival. Access to evidence-based care and prioritizing clinical trials of innovative treatments are essential for advancing ovarian cancer management.Ovarian cancer is the second leading cause of gynecologic cancer deaths globally, with complex outcomes due to late diagnosis and diverse subtypes. Treatment primarily involves debulking surgery and platinum-based chemotherapy, with antiangiogenic agents added for suboptimal debulked and stage IV disease. Recent advancements include the use of PARP inhibitors in maintenance therapy for recurrent and first-line settings, especially in BRCA1/BRCA2 mutation carriers. Deep molecular and cellular profiling are enhancing current investigations, and individualized precision medicine is crucial for improving survival. Access to evidence-based care and prioritizing clinical trials of innovative treatments are essential for advancing ovarian cancer management.